Aardvark Therapeutics, Inc. (NASDAQ:AARD) Stock Has Consensus Target Price of $15.33 According to Brokerages

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD) have been given an average recommendation of “Hold” by the twelve analysts that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $15.33.

AARD has been the subject of several research reports. Weiss Ratings raised shares of Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 2nd. HC Wainwright reiterated a “neutral” rating and issued a $6.00 price target on shares of Aardvark Therapeutics in a research report on Monday, July 20th. Wall Street Zen upgraded shares of Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a $6.00 price objective on shares of Aardvark Therapeutics in a research report on Thursday.

More Aardvark Therapeutics News

Here are the key news stories impacting Aardvark Therapeutics this week:

• Neutral Sentiment: RBC Capital Markets maintained a Hold/Sector Perform view and a $6.00 price target, indicating limited expected upside from recent trading levels. RBC also said ARD-101’s development path could be challenging. Aardvark Therapeutics Gets a Hold from RBC Capital
• Negative Sentiment: Several firms announced or promoted a securities class action covering Aardvark’s February 2025 IPO and trading through May 14, 2026. The complaints allege investors were misled about ARD-101’s safety and efficacy, potentially creating legal costs, liability risk and reputational damage. Pomerantz Class Action Announcement
• Negative Sentiment: The most damaging allegation concerns cardiac safety: the complaint argues that company disclosures described ARD-101 as largely restricted to the gut and free of serious adverse events while failing to adequately disclose cardiac issues that later led to a full FDA clinical hold. If substantiated, the issue could delay development and increase financing risk. Hagens Berman AARD Investor Notice

Insiders Place Their Bets

In other Aardvark Therapeutics news, insider Nelson Sun sold 62,000 shares of the business’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $5.18, for a total transaction of $321,160.00. Following the completion of the sale, the insider owned 35,475 shares of the company’s stock, valued at approximately $183,760.50. The trade was a 63.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 17.80% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp increased its holdings in Aardvark Therapeutics by 30.8% in the 1st quarter. Bank of New York Mellon Corp now owns 29,320 shares of the company’s stock worth $111,000 after acquiring an additional 6,905 shares in the last quarter. Susquehanna International Group LLP purchased a new position in Aardvark Therapeutics during the second quarter valued at approximately $138,000. Ieq Capital LLC purchased a new position in Aardvark Therapeutics during the second quarter valued at approximately $221,000. J. Goldman & Co LP bought a new position in shares of Aardvark Therapeutics in the second quarter worth approximately $233,000. Finally, Renaissance Technologies LLC bought a new position in shares of Aardvark Therapeutics in the first quarter worth approximately $267,000.

Aardvark Therapeutics Price Performance

Shares of AARD opened at $5.06 on Wednesday. The firm has a market capitalization of $110.71 million, a P/E ratio of -1.58 and a beta of 3.74. Aardvark Therapeutics has a one year low of $3.35 and a one year high of $17.94. The business has a fifty day moving average of $6.16 and a 200 day moving average of $5.28.

Aardvark Therapeutics (NASDAQ:AARD) last posted its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.21. Analysts expect that Aardvark Therapeutics will post -3.17 EPS for the current fiscal year.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing oral therapies for obesity, hyperphagia and related metabolic disorders. The company’s approach is based on activating bitter taste receptors, which it believes may influence appetite regulation and metabolic signaling without relying on injectable therapies.

Aardvark’s lead investigational product, ARD-101, is an oral small-molecule bitter taste receptor agonist being studied for conditions involving excessive hunger and food intake, including hyperphagia associated with Prader-Willi syndrome.